From the Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark; Five Prime Therapeutics Inc., South San Francisco, California, USA.
V. Ehrenstein, MPH, DSc, Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; S.L. Andersen, PhD, Biostatistician, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; I. Qazi, PharmD, Senior Clinical Scientist, Five Prime Therapeutics Inc.; N. Sankar, MD, MPH, Medical Director, Clinical Consultant, Five Prime Therapeutics Inc.; A.B. Pedersen, MD, PhD, DMSc, Clinical Associate Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital; R. Sikorski, MD, PhD, Chief Medical Officer, Five Prime Therapeutics Inc.; J.F. Acquavella, PhD, Professor, Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital.
J Rheumatol. 2017 Oct;44(10):1476-1483. doi: 10.3899/jrheum.160816. Epub 2017 Aug 1.
Tenosynovial giant cell tumor (TGCT) is a rare benign proliferative and inflammatory disease arising from synovia of joints, bursae, or tendon sheaths. We aimed to estimate incidence rate and prevalence of TGCT in Denmark, to describe patient characteristics and treatment modalities among patients with TGCT, and to estimate risk of TGCT recurrence.
Using registry data on pathology examinations and inpatient and outpatient hospital diagnoses, we identified adult patients with diagnoses of diffuse TGCT (D-TGCT) or localized TGCT (L-TGCT) between 1997 and 2012, followed through 2012. We described patients' characteristics, treatment modalities, and recurrence.
We identified 2087 patients with L-TGCT and 574 patients with D-TGCT. Their incidence rates per million person-years were 30.3 (95% CI 29.1-31.7) and 8.4 (95% CI 7.7-9.1), respectively. At the end of 2012, prevalence per 100,000 persons was 44.3 (95% CI 42.4-46.3) for L-TGCT and 11.5 (95% CI 10.6-12.6) for D-TGCT. Women made up 61% of the patients with L-TGCT and 51% of the patients with D-TGCT. Median age at diagnosis was 47 years. Ten-year risk of recurrence was 9.8% (95% CI 8.4-11.3%) after L-TGCT and 19.1% (95% CI 15.7-22.7%) after D-TGCT.
This study contributes evidence about epidemiology of TGCT based on routinely collected population-based data gathered in a setting of universal equal access to healthcare and complete followup.
腱鞘巨细胞瘤(TGCT)是一种罕见的良性增生性和炎症性疾病,起源于关节、滑囊或腱鞘的滑膜。我们旨在估计丹麦 TGCT 的发病率和患病率,描述 TGCT 患者的特征和治疗方式,并估计 TGCT 复发的风险。
我们使用病理检查以及住院和门诊诊断的登记数据,确定了 1997 年至 2012 年间诊断为弥漫性 TGCT(D-TGCT)或局限性 TGCT(L-TGCT)的成年患者,并随访至 2012 年。我们描述了患者的特征、治疗方式和复发情况。
我们确定了 2087 例 L-TGCT 患者和 574 例 D-TGCT 患者。他们的每百万人年发病率分别为 30.3(95%可信区间 29.1-31.7)和 8.4(95%可信区间 7.7-9.1)。在 2012 年底,每 10 万人中的患病率分别为 L-TGCT 44.3(95%可信区间 42.4-46.3)和 D-TGCT 11.5(95%可信区间 10.6-12.6)。女性占 L-TGCT 患者的 61%和 D-TGCT 患者的 51%。诊断时的中位年龄为 47 岁。L-TGCT 后的 10 年复发风险为 9.8%(95%可信区间 8.4-11.3%),D-TGCT 后的复发风险为 19.1%(95%可信区间 15.7-22.7%)。
本研究基于普遍获得医疗保健和完整随访的人群为基础的数据,提供了关于 TGCT 流行病学的证据。